ClinicalTrials.Veeva

Menu

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

Pfizer logo

Pfizer

Status and phase

Completed
Phase 2

Conditions

Macular Degeneration

Treatments

Drug: pegaptanib sodium

Study type

Interventional

Funder types

Industry

Identifiers

NCT00239928
A5751015

Details and patient eligibility

About

This study will examine the safety and efficacy of pegaptanib sodium in Japanese patients with wet-type age-related macular degeneration (AMD), who benefit further treatment and who want to continue the treatment after completion of the preceding study (A5751010).

Enrollment

61 patients

Sex

All

Ages

51+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • After completion of the preceding study (A5751010)

Exclusion criteria

  • Serious heart, kidney and/or liver disease
  • Diabetic retinopathy

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

None (Open label)

61 participants in 1 patient group

EYE001
Experimental group
Treatment:
Drug: pegaptanib sodium

Trial contacts and locations

12

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems